Haleon Us Holdings Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HALEON US HOLDINGS, and when can generic versions of HALEON US HOLDINGS drugs launch?
HALEON US HOLDINGS has thirty-one approved drugs.
There are ten US patents protecting HALEON US HOLDINGS drugs.
There are two hundred and three patent family members on HALEON US HOLDINGS drugs in thirty-two countries and sixteen supplementary protection certificates in eight countries.
Summary for Haleon Us Holdings
International Patents: | 203 |
US Patents: | 10 |
Tradenames: | 28 |
Ingredients: | 18 |
NDAs: | 31 |
Drugs and US Patents for Haleon Us Holdings
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Haleon Us Holdings | NICORETTE (MINT) | nicotine polacrilex | GUM, CHEWING;BUCCAL | 018612-003 | Dec 23, 1998 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Haleon Us Holdings | NICORETTE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 018612-004 | Sep 25, 2000 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Haleon Us Holdings | ALLI | orlistat | CAPSULE;ORAL | 021887-001 | Feb 7, 2007 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Haleon Us Holdings
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Haleon Us Holdings | NICORETTE | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 021330-002 | Oct 31, 2002 | 5,110,605 | ⤷ Sign Up |
Haleon Us Holdings | CHILDREN'S ADVIL | ibuprofen | SUSPENSION;ORAL | 020589-001 | Jun 27, 1996 | 4,788,220*PED | ⤷ Sign Up |
Haleon Us Holdings | ABREVA | docosanol | CREAM;TOPICAL | 020941-001 | Jul 25, 2000 | 4,874,794 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HALEON US HOLDINGS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 200 mg/30 mg | ➤ Subscribe | 2004-12-27 |
➤ Subscribe | Capsules | 60 mg | ➤ Subscribe | 2010-09-08 |
➤ Subscribe | Gum | 4 mg | ➤ Subscribe | 2013-01-22 |
➤ Subscribe | Capsules | 200 mg/38 mg | ➤ Subscribe | 2016-02-16 |
➤ Subscribe | Gum | 2 mg | ➤ Subscribe | 2013-01-22 |
International Patents for Haleon Us Holdings Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20080037614 | ⤷ Sign Up |
Japan | 2008540649 | ⤷ Sign Up |
Japan | 4641526 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Haleon Us Holdings Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1519731 | 132013902182575 | Italy | ⤷ Sign Up | PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527 |
2506844 | LUC00077 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
1519731 | 92269 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.